[Hyperlipidemia treated with xiaobu jianfei pian]

Area of Science:

• Integrative Medicine
• Cardiovascular Pharmacology
• Traditional Chinese Medicine (TCM)

Background:

• Hyperlipidemia is a significant risk factor for cardiovascular diseases.
• Traditional Chinese Medicine (TCM) offers potential therapeutic strategies for managing hyperlipidemia.
• The efficacy of specific TCM formulations like Xiaobu Jianfei Pian (XJP) requires rigorous clinical evaluation.

Purpose of the Study:

• To evaluate the lipid-lowering and lipid-adjusting effects of Xiaobu Jianfei Pian (XJP) in patients with hyperlipidemia.
• To compare the efficacy of XJP with Fangfeng Tongsheng San in managing hyperlipidemia.
• To assess the impact of XJP on clinical symptoms and body weight index in hyperlipidemic individuals.

Main Methods:

• A randomized clinical trial involving 51 hyperlipidemia patients.
• Patients were assigned to either the XJP treatment group or the Fangfeng Tongsheng San control group.
• Key lipid parameters (TC, LDL-C, apoB, apoA1, HDL-C) and body weight index were measured and compared between groups.

Main Results:

• XJP significantly reduced total serum cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), and apolipoprotein (apo) B levels (P < 0.001).
• XJP demonstrated marked improvement in clinical symptoms and favorable effects on apoA1/B and TC/HDL-C ratios.
• The XJP group showed a statistically significant reduction in body weight index compared to the control group.

Conclusions:

• Xiaobu Jianfei Pian (XJP) exhibits significant therapeutic effects in lowering and adjusting blood lipids.
• XJP demonstrates superior efficacy over Fangfeng Tongsheng San in managing hyperlipidemia.
• XJP is a promising anti-hyperlipidemia medicine with benefits for lipid profiles, clinical symptoms, and body weight.